Form 8-K · Current report
AbbVie 8-K, filed Oct 30, 2026
- Filed
- CIK
- 0001551152
- Accession no.
- 0001551152-26-000033
Summary
AbbVie reported third-quarter 2026 net revenues of $17.404 billion, up 10.3%, with GAAP diluted EPS of $2.37 and adjusted diluted EPS of $3.82, and raised its full-year 2026 adjusted diluted EPS guidance to $13.95–$13.99 while announcing a 5.2% increase to its 2027 dividend. The company also said it completed its acquisition of Apogee Therapeutics and cited regulatory and clinical progress including FDA approval of Skyrizi for subcutaneous induction in Crohn's disease and positive Phase 3 results for lutikizumab in hidradenitis suppurativa.
Key points
- Third-quarter immunology portfolio net revenues were $9.165 billion, up 16.3%, including Skyrizi at $5.776 billion and Rinvoq at $2.706 billion, while Humira fell 31.2% to $683 million.
- Neuroscience portfolio net revenues rose 19.4% to $3.389 billion; oncology rose 0.8% to $1.696 billion; aesthetics fell 1.4% to $1.176 billion.
- The Apogee Therapeutics acquisition includes zumilokibart, a late-stage IL-13 antibody for atopic dermatitis, and APG273, a long-acting IL-13/TSLP combination for asthma.
- The FDA approved Skyrizi for subcutaneous induction in moderately to severely active Crohn's disease, and the Phase 3 INTREPID study of lutikizumab met its primary endpoint in hidradenitis suppurativa.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02 Results of Operations and Financial Condition On October 30, 2026, AbbVie Inc. issued a press release announcing financial results for the third quarter ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference. Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Exhibit 99.1 Press Release dated October 30, 2026 (furnished pursuant to Item 2.02). 104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101). …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.